Weight Loss News and Research

Latest Weight Loss News and Research

Study demonstrates safety of weight reduction surgery in morbidly obese adolescents

Today, about one in five children in the United States are obese. That means that in just one generation alone the number of obese kids in this country has quadrupled.

1 Feb 2012

Crizotinib can treat ROS1-driven tumors

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S.

1 Feb 2012

Oral HPV infection more common in men than women: Study

According to a new US study, oral human papillomavirus (HPV) infection is more common among men than women, leading to an increased risk for men of head and neck cancers. HPV causes the majority of cervical cancers, as well as genital and anal - and head and neck cancers.

31 Jan 2012

Obese docs often miss obesity in their patients: Study

According to researchers at Johns Hopkins University physicians with normal body mass index or weight-to-height ratios are more likely to discuss weight loss with patients than overweight doctors.

31 Jan 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

Dairy products help weight loss: Study

For these findings the researchers reviewed 14 clinical trials involving 883 adults. The trials looked at how eating dairy food impacted on people's weight, body fat, waistlines and lean muscle mass. In the study published in the International Journal of Obesity, the authors said they wanted to reveal more about the relationship between weight loss and dairy consumption.

31 Jan 2012

Neutra closer to delivering Pure Plus weight-loss supplement

Neutra Corp., an emerging provider of innovative nutraceuticals, announced today that it is one step closer to delivering its revolutionary Pure Plus weight-loss supplement to market.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

Inlyta receives FDA approval for treatment of advanced kidney cancer

The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

30 Jan 2012

Vanderbilt Center for Surgical Weight Loss develops online education seminar for patients

The Vanderbilt Center for Surgical Weight Loss is developing an online education seminar for prospective patients to take in the privacy of their own homes.

30 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

$Coexisting comorbidities increase treatment costs for older adults with hip fractures$

Coexisting comorbidities increase treatment costs for older adults with hip fractures

More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.

19 Jan 2012

New hypothesis seeks to explain how stress can cause obesity

Stress can make you fat - and being obese can create stress. A new hypothesis seeks to explain how. Diet and lack of exercise are not sufficient to explain the worldwide rise in obesity. Stress is one of many other factors which could contribute, according to human biologist Brynjar Foss from the University of Stavanger.

19 Jan 2012

New pathways in battle against obesity and other lifestyle diseases

The world is encountering an epidemic of obesity, heart disease and diabetes. In the west it is already widespread and it is now exploding in the developing world with the rapid change in the lifestyles of recent generations.

18 Jan 2012

Gastric bypass superior to lap banding finds study

A new study evaluates the best option in terms of weight loss surgery for those who need it. Researchers found gastric bypass patients lose more weight than gastric banding patients and keep it off longer. Even though banding is a simpler operation, nearly half of those patients were still obese after six years.

17 Jan 2012

Neutracorp finalizes new proprietary weight-loss formula

Neutracorp announced today that it has finalized its new proprietary weight-loss formula—including an all-natural Bio-Energy Boost that could help make losing weight easier and faster than ever before.

17 Jan 2012

Hormone that burns energy discovered

Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.

16 Jan 2012

Eating out without gaining too much weight

According to a new study eating out does not necessarily have to mean consuming large portions of high-calorie foods and becoming obese.

12 Jan 2012

Nature journal publishes Ember's brown fat biology data

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data supporting its lead brown fat biology program in the journal Nature.

12 Jan 2012